NRX-101: Ph IIb/III started

NeuroRx began a double-blind Phase IIb/III trial to compare twice-daily oral NRX-101 containing 175 or 237.5 mg D-cycloserine and 8.25, 16.5 or 33 mg lurasidone vs. Latuda lurasidone for up to 6 weeks...